Treatment of Active Giant Cell Arteritis Without Acute Visual Loss or Amaurosis Fugax
This protocol addresses patients with confirmed active giant cell arteritis (GCA) who present without acute visual loss and without amaurosis fugax — a clinically important distinction that directly shapes the initial treatment strategy.
Clinical Scenario
Active GCA is established, but the patient has no acute ocular manifestations — neither acute visual loss nor amaurosis fugax. This absence of sight-threatening symptoms is a key clinical qualifier. Current evidence reserves high-dose intravenous pulse glucocorticoid therapy for patients with GCA-related visual symptoms; in this setting, oral therapy is the appropriate foundation.
Treatment Goals
The target is remission: complete absence of all clinical signs and symptoms attributable to active giant cell arteritis, together with normalisation of inflammatory markers — ESR and CRP.
Treatment Approach (Overview)
Management centres on high-dose oral glucocorticoid therapy initiated promptly to induce remission, followed by a structured tapering schedule aimed at reaching progressively lower maintenance doses. The complete regimen — including specific dose targets, tapering milestones, and duration — is detailed in the full protocol.
References
DOI: 10.1136/annrheumdis-2019-215672
- The task force recommends limiting the use of intravenous pulse GC therapy to patients with complicated GCA such as those with GCA-related visual symptoms.
- High dose glucocorticoid (GC) therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active GCA or TAK.
- Once disease is controlled, we recommend tapering the GC dose to a target dose of 15–20 mg/day within 2–3 months and after 1 year to ≤5 mg/day (for GCA) and to ≤10 mg/day (for TAK).
- Absence of all clinical signs and symptoms attributable to active LVV and normalisation of ESR and CRP.